3 Biotech ETFs That Could Double Your Money by 2025 With Zero Effort
Between the unpredictable twists and turns of the clinical trial process and the endless mysteries of human health, investing in biotech stocks is quite risky. Apparently promising treatment candidates often fail, and most investors lack the scientific background necessary to make an informed assessment of the merits of a company's technology platform or the medications it has in development.
So, for those seeking to profit from the biotech industry's long-term growth -- which by all indications is just getting started -- buying exchange-traded funds (ETFs) rather than individual stocks can be a solid strategy. These ETFs own a bucket of stocks across the industry, so while the stunning success of any individual company won't have a huge impact on your investment returns, the failure of another won't take a major bite out of them, either.
There's an array of biotech ETF options available to investors, each with its own thematic focuses and risk profile, but I favor these three for a simple, compelling reason: They have histories of outperforming the market.
Source Fool.com
